Modulation of human peripheral blood mononuclear cell activation by the combination of leflunomide and pentoxifylline.
Stojic Vukanic
Z
Z
Institute of Microbiology and Immunology, School of Pharmacy, MMA, Belgrade, Yugoslavia.
Dimitrijevic
M
M
Colic
M
M
Popovic
P
P
Jandric
D
D
D000814:Aniline Compounds / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D002478:Cells, Cultured; D003437:Crotonates; D004347:Drug Interactions; D006801:Humans; D006885:Hydroxybutyrates / Q000494:pharmacology*; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007555:Isoxazoles / Q000494:pharmacology*; D000077339:Leflunomide; D008213:Lymphocyte Activation / Q000187:drug effects*; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology*; D009570:Nitriles; D010431:Pentoxifylline / Q000494:pharmacology*; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D014052:Toluidines
D000814:Aniline Compounds; D003437:Crotonates; D006885:Hydroxybutyrates; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D009570:Nitriles; D010726:Phosphodiesterase Inhibitors; D014052:Toluidines; C527525:teriflunomide; D000077339:Leflunomide; D010431:Pentoxifylline